公开(公告)号：EP3473624A1

公开(公告)日：2019-04-24

申请号：EP17815698.0

申请日：2017-06-20

申请人： Daegu-Gyeongbuk Medical Innovation Foundation

发明人： CHOI, Hwan Geun ,  SON, Jung Beom ,  KIM, Shinae ,  LEE, Seungyeon ,  KO, Eunhwa ,  CHO, Joongheui ,  KANG, Seock Yong ,  KIM, So Young ,  PARK, Jin-Hee ,  KO, Yi Kyung ,  RYU, Hee Yoon ,  KIM, Nam Doo ,  KIM, Hyunkyoung ,  LEE, Younho ,  LEE, Sun-Hwa ,  KIM, Dayea ,  LEE, Sun Joo ,  HONG, Seongho ,  MIN, Sang Hyun ,  LEE, Sungwoo ,  CHOI, Dong Kyu ,  BAE, Jae Hyun ,  HONG, Eunmi ,  JANG, Tae-ho ,  SONG, Jaeyoung ,  KIM, Sangbum ,  YOON, Suk Kyoon

IPC分类号： C07D471/04 ,  A61K31/437 ,  A23L33/105

摘要： The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.
Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.

公开(公告)号：EP4065553A1

公开(公告)日：2022-10-05

申请号：EP21741012.5

申请日：2021-01-15

申请人： Daegu-Gyeongbuk Medical Innovation Foundation ,  PimedBio, Inc.

发明人： IM, Chun Young ,  MIN, Sang Hyun ,  YU, Ji Hoon ,  KO, Eun Bi ,  KIM, So Young ,  LEE, Seungyeon ,  CHOI, Dong Kyu ,  LEE, Heejin ,  PARK, Ga Young ,  LEE, Doohyun ,  HONG, Eunmi ,  JEON, Hui-Jeon ,  PARK, Young-Hoon ,  HAN, Ye Ri ,  KIM, Nam Hui ,  KIM, Jun Woo ,  OH, Bae Jun ,  PARK, Jeong-Eun ,  SEO, Chang Hoon ,  SONG, Minsoo ,  RO, Seonggu ,  SHIN, Dongkyu

IPC分类号： C07C311/16 ,  C07C303/36 ,  A61K31/18 ,  A61P35/00 ,  A61P29/00 ,  A61P3/00 ,  A23L33/10

公开(公告)号：EP3949959A1

公开(公告)日：2022-02-09

申请号：EP20783558.8

申请日：2020-04-06

申请人： Daegu-Gyeongbuk Medical Innovation Foundation

发明人： KIM, Jun Woo ,  MIN, Sang Hyun ,  LEE, Heejin ,  KWON, Oh Bin

IPC分类号： A61K31/24 ,  A61K31/704 ,  A61K45/06 ,  A61P35/00 ,  A23L33/10

摘要： The present invention relates to a pharmaceutical composition comprising trimebutine as an active ingredient for prevention or treatment of cancer. Having an excellent effect of selectively inhibiting growth and proliferation of cancer stem cells, the pharmaceutical composition can suppress the recurrence, metastasis, and progression of cancer even when used alone. Thus, the composition can be advantageously used as a pharmaceutical composition for prevention or treatment of cancer or in combination with other agents.